pangenotypic

Velpatasvir (GS-5816), also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. GS-5816 has demonstrated pan-genotypic activity and a high barrier to resistance in HCV replicon assays. GS-5816 demonstrated pangenotypic antiviral activity in patients with genotype 1-4 HCV infection. It will be further evaluated in combination with other pangenotypic direct-acting antivirals to achieve the goal of developing a well-tolerated, highly effective treatment for all HCV genotypes.

Bemnifosbuvir (AT-511), a novel phosphoramidate prodrug of 2'-fluoro-2'-C-methylguanosine-5'-monophosphate, exhibits potent in vitro activity against HCV.

Voxilaprevir is an inhibitor of hepatitis C virus (HCV) nonstructural (NS) protein 3 4A protease.

Coblopasvir is a pan-genotypic non-structural protein 5A (NS5A) inhibitor. It can be used to study chronic hepatitis C virus infection.

Coblopasvir dihydrochloride can be used to study chronic HCV infection and is a pan-genotypic nonstructural protein 5A (NS5A) inhibitor.

Bemnifosbuvir hemisulfate (AT-527) is a potent inhibitor of HCV virus replication.